Orforglipron is the first oral small-molecule GLP-1 receptor agonist to reach the market, and on April 1, 2026 the FDA approved orforglipron under the brand name Foundayo for chronic weight management. Getting there took a clinical program that ran from a 2023 first-in-human readout through three pivotal Phase 3 trials. This is the story of that program, trial by trial, with the numbers each study actually reported.
The headline efficacy figure — roughly 12% mean weight loss at the top dose — is modest next to the injectable heavyweights. What sets orforglipron apart is not peak potency but format: a once-daily pill, chemically synthesized rather than grown as a peptide, with no injection and no cold chain. That distinction runs through the entire trial narrative below.
Research-context information only. Orforglipron (brand name Foundayo) is an oral small-molecule GLP-1 receptor agonist that the FDA approved in April 2026 for chronic weight management; its type 2 diabetes indication remained under review as of publication. The trial designs, doses, and adverse-event rates reported below come from published clinical trials and regulatory filings. Research-peptide vendors may separately offer orforglipron material for laboratory research; such material is not the approved Foundayo product, is not FDA-approved, and is not intended for human use. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
The Molecule
Orforglipron (development code LY3502970) is a once-daily, non-peptide small-molecule GLP-1 receptor agonist. It was discovered by Chugai and licensed to Eli Lilly in 2018. Because it is a synthesized small molecule rather than a peptide, it can be manufactured without the injectable fill-and-finish and cold-chain constraints that limit peptide-based GLP-1 products — the scalability argument that has driven much of the commercial interest.
Reported pharmacology supports once-daily oral dosing: oral bioavailability in the roughly 30–40% range and a half-life of approximately 24–38 hours. Unlike oral semaglutide, which requires fasting and specific water-intake rules, orforglipron carries no food or water timing restriction. As a non-peptide, it is also expected not to be immunogenic.
Phase 1b: First Human Data (2023)
The first-in-human work was published by Pratt and colleagues in Diabetes, Obesity and Metabolism in 2023. This early-phase study characterized the safety and pharmacokinetics that justified a once-daily oral schedule and set up the dose range explored in the Phase 2 program. It was a foundation study rather than an efficacy readout, but it established that a small-molecule GLP-1 agonist could achieve the sustained exposure an injectable peptide normally provides.
Phase 2: The Signal Gets Strong (2023)
Two Phase 2 trials, both published in 2023, turned orforglipron from a promising molecule into a serious contender.
Obesity (NCT05051579). The Phase 2 obesity trial, published in the New England Journal of Medicine in 2023, tested doses of 12, 24, 36, and 45 mg. It reported up to 14.7% mean weight loss at 36 weeks on the top dose. The proportion of participants reaching at least 10% weight loss climbed from 47% on the 12 mg dose to 75% on the 36 mg dose, versus 9% on placebo.
Type 2 diabetes (NCT05048719). Frias and colleagues published the Phase 2 diabetes trial in The Lancet in 2023. Over 26 weeks it compared 3, 12, 24, 36, and 45 mg doses against both placebo and the active comparator dulaglutide 1.5 mg. It reported A1c reductions of up to 2.1%, versus 0.4% for placebo and 1.1% for dulaglutide, with 65–96% of participants reaching an A1c below 7% depending on dose. Beating an active injectable comparator on glucose control was the result that moved the program into a full Phase 3 build-out.
Phase 3: The Pivotal Program
Three Phase 3 trials anchored the regulatory package — one in obesity, one in obesity with diabetes, and one in early type 2 diabetes.
ATTAIN-1 (obesity, NCT05869903). This 72-week trial enrolled 3,127 adults with obesity, no diabetes required. On the efficacy estimand, mean weight reduction was 7.8% at 6 mg, 9.3% at 12 mg, and 12.4% (about 27.3 lb) at 36 mg, versus 0.9% for placebo. At the 36 mg dose, 59.6% of participants reached at least 10% weight loss and 39.6% reached at least 15%. Adverse-event discontinuation rose with dose — 5.1%, 7.7%, and 10.3% across the 6, 12, and 36 mg arms, versus 2.6% for placebo. These results were published by Aronne and colleagues in the New England Journal of Medicine in 2025.
ATTAIN-2 (obesity with type 2 diabetes, NCT05872620). Published in The Lancet in 2025, this 72-week trial enrolled roughly 1,600 adults who had both obesity and type 2 diabetes. Mean weight reduction was 5.5% at 6 mg, 7.8% at 12 mg, and 10.5% (about 22.9 lb) at 36 mg, versus 2.2% for placebo. On glucose control, the 36 mg dose reported an A1c reduction of 1.8% from a baseline of 8.1%, with 75% of participants reaching an A1c at or below 6.5%. The gastrointestinal adverse-event pattern held: at 36 mg versus placebo, the trial reported nausea 36.4% vs 8.4%, vomiting 23.1% vs 3.8%, diarrhea 27.4% vs 15.0%, and constipation 22.4% vs 7.8%, with adverse-event discontinuation of 10.6% vs 4.6%.
ACHIEVE-1 (early type 2 diabetes, NCT05971940). Rosenstock and colleagues published this 40-week trial of 559 adults with early type 2 diabetes in the New England Journal of Medicine in 2025. From a baseline A1c of 8.0%, reductions were 1.3% at 3 mg, 1.6% at 12 mg, and 1.5% at 36 mg, versus 0.1% for placebo, with roughly 73–76% of participants reaching an A1c below 7% versus 28% on placebo. Weight loss at 40 weeks was 4.7%, 6.1%, and 7.9% (about 16.0 lb) across the 3, 12, and 36 mg doses, versus 1.6% for placebo. ACHIEVE-1 used a titration schedule starting at 1 mg and stepping up every four weeks.
Here is the pivotal program at a glance:
| Trial | Population | Duration | Top-dose weight loss | Top-dose A1c change |
|---|---|---|---|---|
| ATTAIN-1 | Obesity, no diabetes | 72 wk | 12.4% (36 mg) | — |
| ATTAIN-2 | Obesity + T2D | 72 wk | 10.5% (36 mg) | −1.8% |
| ACHIEVE-1 | Early T2D | 40 wk | 7.9% (36 mg) | −1.5% |
Figures are the primary reported values from each trial. Trials differ in population and duration and are not directly comparable to one another.
Efficacy in Context
The honest read on orforglipron is that its weight-loss magnitude sits below the injectable frontrunners. This is an indirect, cross-trial comparison — the studies enrolled different populations over different durations and were never run head-to-head — but the gaps are large enough to be informative.
| Compound | Trial | Class | Top-dose weight loss |
|---|---|---|---|
| Orforglipron 36 mg | ATTAIN-1 (72 wk) | Oral GLP-1 (single agonist) | 12.4% |
| Tirzepatide 15 mg | SURMOUNT-1 (72 wk) | Injectable GLP-1/GIP (dual) | ~20.9–22.5% |
| Retatrutide 12 mg | Phase 2 (48 wk) | Injectable GLP-1/GIP/glucagon (triple) | 24.2% |
Tirzepatide's SURMOUNT-1 trial (published by Jastreboff and colleagues in the New England Journal of Medicine in 2022) reported roughly 20.9–22.5% weight loss at its 15 mg dose, and retatrutide — still an investigational drug with no FDA approval — reported 24.2% at 12 mg in its Phase 2 obesity trial (Jastreboff and colleagues, 2023). On glucose control the same ordering holds: orforglipron's A1c reductions of roughly 1.5–1.8% trail the roughly 2.3% reported for tirzepatide.
The pattern is consistent with mechanism. Orforglipron acts on a single receptor (GLP-1), tirzepatide on two (GLP-1 and GIP), and retatrutide on three (GLP-1, GIP, and glucagon). More receptor engagement has tracked with more weight loss across these programs. Orforglipron's differentiator is therefore the delivery format — an oral tablet at manufacturing scale — not peak efficacy against the injectables.
Safety Profile
Across the trials the adverse-event profile was gastrointestinal, dose-dependent, and concentrated during titration. In ATTAIN-1, comparing the 36 mg dose with placebo, trials reported nausea 33.7% vs 10.4%, vomiting 24.0% vs 3.5%, diarrhea 23.1% vs 9.6%, constipation 25.4% vs 9.3%, and dyspepsia 14.1% vs 5.0%. ACHIEVE-1 showed the same signature at lower absolute rates — at 36 mg versus placebo, diarrhea 26% vs 9%, nausea 16% vs 2%, vomiting 14% vs 1%, dyspepsia 15% vs 7%, and constipation 14% vs 4%.
Adverse-event discontinuation reached roughly 10% at the top dose across the program. On laboratory safety, the Phase 1–2 data showed no clinically meaningful signal in liver enzymes (ALT, AST, ALP) or bilirubin, and no pancreatitis, retinal, or optic-neuropathy signal had emerged as of approval, with post-approval pharmacovigilance ongoing.
